FDA accepts new drug application for pruritis treatment odevixibat

The FDA accepted a new drug application for odevixibat for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis, according to a press release.According to the manufacturer, Alibreo Pharma, the once-daily, non-systemic ileal bile acid transport inhibitor was granted priority review and set a goal date of July 20, 2021, for Prescription Drug User Fee Act approval.“Odevixibat has the potential to become the first approved drug treatment for patients with [progressive familial intrahepatic cholestasis],” Ron Cooper, president and CEO of Albireo,Read More

Share on facebook
Share on twitter
Share on linkedin